Press Releases

DAY HI:
DAY LOW:
VOLUME:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

Date Title Format
Jul 27, 2023
Stockholders From Both Assertio and Spectrum Have Overwhelmingly Voted in Support of the Transaction Transaction Expected to be Significantly Accretive to Assertio in 2024 LAKE FOREST, Ill., and BOSTON -- July 27, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc.
Jul 20, 2023
Recommendations from the Nation’s Leading Independent Proxy Advisory Firms Recognize Value Creation Opportunity for Spectrum Stockholders and Strength of the Combined Company BOSTON --(BUSINESS WIRE)--Jul. 20, 2023-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or the “Company”)
May 17, 2023
BOSTON --(BUSINESS WIRE)--May 17, 2023-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical Company focused on novel and targeted oncology announced today that on May 16, 2023 , the Company received a written notification from the Listing
May 09, 2023
-- Q1 2023 net sales of $15.6 million , an increase of 54% compared to Q4 2022 -- -- Company to be acquired by Assertio Holdings, Inc. , delivering value to stakeholders in an all stock and contingent value rights (CVR) transaction -- -- Transaction expected to close in Q3 2023 -- BOSTON
Apr 25, 2023
  Assertio Holdings, Inc. to Acquire Spectrum Pharmaceuticals, Inc. in All Stock and CVR Transaction Complementary Commercial Growth Platforms Anticipated to Accelerate ROLVEDON™ (eflapegrastim-xnst) Injection Profitability and Diversify Revenue Streams Combination of Assertio’s Omni-Channel
Mar 22, 2023
-- First launch quarter for ROLVEDON™ (eflapegrastim-xnst) injection -- -- Q4 and full year net sales of $10.1 million -- -- Management to host webcast and conference call today at 8:30 a.m. ET / 5:30 a.m. PT -- BOSTON --(BUSINESS WIRE)--Mar. 22, 2023-- Spectrum Pharmaceuticals, Inc.
Mar 17, 2023
BOSTON --(BUSINESS WIRE)--Mar. 17, 2023-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the fourth quarter and full year 2022 financial results and provide a
Feb 08, 2023
BOSTON --(BUSINESS WIRE)--Feb. 8, 2023-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology announced today that a permanent J-code, J1449, has been issued for ROLVEDON (eflapegrastim-xnst) Injection by the U.S.
Jan 31, 2023
-- Preliminary unaudited Q4 2022 net sales expected to be approximately $10 million -- -- Cash, cash equivalents and marketable securities of $75 million at 12/31/2022, which is expected to extend cash runway through 2024 -- BOSTON --(BUSINESS WIRE)--Jan. 31, 2023-- Spectrum Pharmaceuticals, Inc.
Jan 26, 2023
-- Commercial employee (non-executive) who was hired specifically for the launch of ROLVEDON™ (eflapegrastim-xnst) injection is the recipient of this grant -- BOSTON --(BUSINESS WIRE)--Jan. 26, 2023-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and
Jan 04, 2023
BOSTON --(BUSINESS WIRE)--Jan. 4, 2023-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that Francois J. Lebel , M.D., Executive Vice President and Chief Medical Officer, will step down from his role to
Dec 27, 2022
-- Commercial employees (non-executive) who were hired specifically for the launch of ROLVEDON™ (eflapegrastim-xnst) injection are the recipients of this grant -- BOSTON --(BUSINESS WIRE)--Dec. 27, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and
Dec 06, 2022
BOSTON --(BUSINESS WIRE)--Dec. 6, 2022-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology announced today that ROLVEDON (eflapegrastim-xnst) has been added to the latest National Comprehensive Cancer Network® Supportive Care
Dec 05, 2022
-- Commercial employees (non-executive) who were hired specifically for the launch of ROLVEDON™ (eflapegrastim-xnst) injection are the recipients of this grant -- BOSTON --(BUSINESS WIRE)--Dec. 5, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and
Nov 25, 2022
— Immediately de-prioritizes poziotinib program, accelerates cost reductions, including 75% reduction in R&D related workforce — — Spectrum to explore strategic alternatives for the poziotinib program, including partnerships and business development opportunities — BOSTON --(BUSINESS WIRE)--Nov.
Nov 10, 2022
-- ROLVEDON™ (eflapegrastim-xnst) injection is now commercially available -- -- Cash runway expected to extend through 2024 -- -- Management to host webcast and conference call today at 4:30 p.m. ET / 1:30 p.m. PT -- BOSTON --(BUSINESS WIRE)--Nov. 10, 2022-- Spectrum Pharmaceuticals, Inc.
Nov 03, 2022
BOSTON --(BUSINESS WIRE)--Nov. 3, 2022-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the third quarter 2022 financial results and provide a corporate update
Oct 21, 2022
-- Distribution partners stocked with product and ready to sell into estimated $2 billion market -- BOSTON --(BUSINESS WIRE)--Oct. 21, 2022-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical company focused on novel and targeted oncology therapies,
Sep 23, 2022
-- Multiple tranche debt financing provides Spectrum with up to $65 million -- -- Funding provides additional capital to optimize commercial launch of ROLVEDON™ -- -- Cash runway extended through 2024 -- BOSTON --(BUSINESS WIRE)--Sep. 23, 2022-- Spectrum Pharmaceuticals, Inc.
Sep 22, 2022
BOSTON --(BUSINESS WIRE)--Sep. 22, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the U.S. Food and Drug Administration’s (“FDA”) Oncologic Drugs Advisory Committee
Displaying 1 - 20 of 899